Skip to content

Use Misoprostol to Optimize Prevention of Cervical Cancer

Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06669533
Acronym
MISOPCx
Enrollment
420
Registered
2024-11-01
Start date
2025-02-25
Completion date
2028-11-11
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancers

Keywords

cervical cancers

Brief summary

This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.

Interventions

DRUGPlacebo

Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

DRUGMisoprostol

Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER
Cameroon Baptist Convention Health
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Masking description

The PIs, nurses who will be providing the drugs, and study participants will be blinded in the study.

Eligibility

Sex/Gender
FEMALE
Age
25 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of Type 3 TZ confirmed on exam prior to randomization * Age 25 years or older

Exclusion criteria

* With Type 1 or 2 TZ prior to randomization * Currently pregnant * History of hysterectomy * Any cancerous lesions * Active cervicitis

Design outcomes

Primary

MeasureTime frameDescription
Conversion rate from Type 3 transformation zone (TZ) to Types 1 or 2Approximately 2-3 hours and approximately 4-6 hours since drug administrationThe rate of participants with successful transformation from Type 3 (TZ) to Type 1 or 2 (TZ) will be calculated. It is the number of participants who successfully transformed from Type 3 TZ to Type 1 or 2 TZ, divided by the total number of participants in the entire randomized cohort.

Secondary

MeasureTime frameDescription
Comparison of the rate of patients converted from Type 3 TZ to Type 1 or 2 TZ between 2-3 hours and 4-6 hoursApproximately 2-3 hours vs approximately 4-6 hoursThe rate of transformation from Type 3 transformation zone (TZ) to Type 1 or 2 TZ between 2-3 hours and 4-6 hours after administering misoprostol will be compared. The rate is calculated as the number of successful transformations within each time period (2-3 hours or 4-6 hours) divided by the total cohort.

Countries

Cameroon

Contacts

CONTACTWarner K Huh, MD
whuh@uabmc.edu2059341555
CONTACTSimon M Manga, PhD
smanga@uab.edu2059345612
PRINCIPAL_INVESTIGATORWarner K Huh, MD

University of Alabama at Birmingham

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026